News

Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma DURHAM, NC, January 10, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has…

Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab for Patients with Recurrent Glioblastoma DURHAM, NC, November 30, 2020 – Istari Oncology, Inc., a clinical-stage biotechnology company, today announced the…

From the office of University Hospitals Seidman Cancer Center: UH Seidman Cancer Center Opens New Trial with PVSRIPO, a Viral-based Immunotherapy in Combination with Pembrolizumab for Patients with Recurrent GBM The two therapies may be able to generate a potent…

Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma Phase 2 clinical study expected to begin in First Quarter 2021 DURHAM, NC, November 16, 2020 –…

For the full poster on the Phase 1 trial click the button below.

Journal authors for the below study: Mubeen M. Mosaheb, Elena Y. Dobrikova, Michael C. Brown, Yuanfan Yang , Jana Cable, Hideho Okada, Smita K. Nair, Darell D. Bigner, David M. Ashley & Matthias Gromeier Viruses naturally engage innate immunity, induce…

Journal authors for the below study: Jonathan P. Kastan, Elena Y. Dobrikova, Jeffrey D. Bryant, Matthias Gromeier Cells respond to environmental stress with coordinated transcriptional, translational, and posttranslational gene expression changes. The pivotal event in the integrated stress response (ISR)…